Skip to main content
. 2019 May 17;19:158. doi: 10.1186/s12887-019-1504-9

Table 1.

Characteristics of the trials included in the analysis

Author Year Patient age
(treatment/control)		 Setting Design Cases Disease course Initial treatmenta
(treatment/control)		 Retreatmenta (treatment/control) Follow-up NOS
/MINORS
Burns et al. [14] 2008 22/20 months US RCT 12/12 2–7 days IVIG 2 Infliximab 5/IVIG 2 Study entry
1–2 weeks
6–8 weeks
< 7 months		 –
Youn et al. [15] 2016 3 months-13 years Korea RCT 11/32 3–8 days IVIG 2 Infliximab 5/IVIG 2 Study entry
2–4 weeks		 –
Tremoulet et al. [16] 2014 3.0/2.8 years US RCT 98/98 3–10 days IVIG 2 + Infliximab 5
IVIG 2 + Normal saline		 IVIG 2 Study entry
2–5 weeks		 –
Son et al. [27] 2011 23/29 months US Retrospective 20/86 4–7 days IVIG 2 Infliximab 5/IVIG 2 Study entry
1–10 weeks		 8
Masaaki et al. [28] 2018 2.5/3.0 years Japan RCT 16/15 6-7 days IVIG 2 Infliximab 5 Study entry
8 week		 –
Miura et al. [8] 2005 N/A Japan RCT 11/11 N/A IVIG 2 IVMP 30 for 3 consecutive days/IVIG 2 Study entry
1 week		 –
Furakawa et al. [9] 2007 31.3/28.1 months Japan Non-RCT 44/19 N/A IVIG 2 IVMP 30 for 3 consecutive days/IVIG 2 4 weeks 19
Miura et al. [10] 2008 32 ± 19/32 ± 26 months Japan RCT 7/8 4–5 days IVIG 2 IVMP 30 for 3 consecutive days/IVIG 2 Study entry
1 week		 –
Ogata et al. [11] 2009 14 ± 17/33 ± 24 months Japan RCT 13/14 4–5 days IVIG 2 IVMP 30 for 3 consecutive days/IVIG 2 Before discharge –
Teraguchi et al. [12] 2013 1–120 months Japan Non-RCT 14/27 N/A IVIG 2 IVMP 30 for 3 consecutive days 4 weeks 20
Sundel et al. [30] 2003 4.3/4.5 years US RCT 18/21 6.5/6.9 days IVIG 2 + IVMP 30/IVIG 2 N/A 2 and 6 weeks –
Newburger et al. [29] 2007 2.9/2.9 years US RCT 101/97 4–10 days IVIG 2 + IVMP 30/IVIG 2 IVIG 2 Study entry
1 and 5 weeks		 –

aIVIG g kg−1 day− 1, IVMP mg kg− 1 day− 1, Infliximab mg kg− 1 day− 1, N/A Not available